Published in Clin Med Insights Oncol on March 16, 2016
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | NCT01685268
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | NCT01867333
XL-184+Abiraterone in Post-Chemo CRPC | NCT01574937
AMG 386 and Abiraterone for Advanced Prostate Cancer | NCT01553188
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer | NCT02407054
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | NCT02204072
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
The Cohesive Metastasis Phenotype in Human Prostate Cancer. Biochim Biophys Acta (2016) 0.76
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel) (2017) 0.75
The feasibility of using mutation detection in ctDNA to assess tumor dynamics. Int J Cancer (2017) 0.75
Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Des Devel Ther (2016) 0.75
Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget (2017) 0.75
Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer. Curr Genomics (2017) 0.75
Androgen receptor regulation of local growth hormone in prostate cancer cells. Endocrinology (2017) 0.75
Inhibition of Androgen Receptor Nuclear Localization and Castration Resistant Prostate Tumor Growth by Pyrroloimidazole-Based Small Molecules. Mol Cancer Ther (2017) 0.75
Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. Ther Adv Med Oncol (2017) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol (2014) 3.10
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 2.87
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer (2003) 2.43
New therapies for castration-resistant prostate cancer. N Engl J Med (2010) 2.37
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer (1999) 2.34
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2014) 2.23
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 2.12
Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med (2015) 2.01
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
The androgen receptor gene mutations database: 2012 update. Hum Mutat (2012) 1.84
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther (2013) 1.81
Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem (2002) 1.80
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res (2012) 1.72
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Clin Cancer Res (2015) 1.58
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia (2013) 1.49
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res (2013) 1.43
Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res (2009) 1.41
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res (2002) 1.29
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res (2014) 1.27
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol (1998) 1.20
New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle (2010) 1.16
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer (2002) 1.13
Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res (2013) 1.13
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer (2015) 1.04
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal (2014) 1.03
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther (2009) 1.02
REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer. Nucleic Acids Res (2013) 1.02
Decoding the androgen receptor splice variants. Transl Androl Urol (2013) 1.01
Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res (2011) 0.99
Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate (2013) 0.98
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget (2015) 0.94
Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov (2011) 0.93
"Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer. J Investig Med (2010) 0.92
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One (2012) 0.92
p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res (2014) 0.90
Association of glucocorticoid receptors with prostate nuclear sites for androgen receptors and with androgen response elements. J Mol Endocrinol (1990) 0.88
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res (2015) 0.86
What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer? Clin Dev Immunol (2013) 0.82
Liquid biopsy: Clues on prostate cancer drug resistance. Sci Transl Med (2015) 0.78
Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother (2015) 0.77